U
FLXN

UBS’s Flexion Therapeutics, Inc. FLXN Stock Holding History

UBS’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$20K Sell
1,122
-281
-20% -$4.07K ﹤0.01% 8036
2014
Q2 		$19K Buy
1,403
+1,192
+565% +$16.2K ﹤0.01% 8165
2014
Q1 		$3K Buy
+211
New +$3.65K ﹤0.01% 9890

Other funds holding FLXN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's FLXN Position: Q3 2014 in Review

UBS reduced its Flexion Therapeutics, Inc. (FLXN) stake by 20% in Q3 2014, selling an estimated $4.07K and leaving 1,122 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #8036.

UBS first reported a position in FLXN in Q1 2014 and has held it in 3 quarters since. 38 funds tracked by Wall St. Rank hold FLXN as of Q3 2014.

  • UBS held 1,122 shares of Flexion Therapeutics, Inc. worth $20K as of Q3 2014.
  • UBS sold 281 Flexion Therapeutics, Inc. shares in Q3 2014, an estimated $4.07K.
  • Flexion Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8036 holding.
  • UBS first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and has held it in 3 quarters since.
  • 38 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.